Publication
Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.
Perrine Moyer, Thibaut Leguay, Maxime Jullien, Françoise Huguet, Gabrielle Roth-Guepin, Yosr Hicheri, Amine Belhabri, Thomas Cluzeau, Ana Berceanu, Emmanuelle Tavernier, Stéphane Leprêtre, Karin Bilger, Pascal Turlure, Jean-Noel Bastié, Marie Balsat, Magda Alexis, Eolia Brissot, Delphine Lebon, Emmanuel Raffoux, Stefan Wickenhauser, Victoria Cacheux, Anne Banos, Sarah Bonnet, Nicolas Boissel, Hervé Dombret, Philippe Rousselot, Patrice Chevallier
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Inotuzumab (InO)-based frontline regimens have significantly improved the survival of older patients with Philadelphia-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL). Yet, outcome after relapse is not reported for this population. METHODS: The retrospective RELAPSINO study…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT03249870registry_reference1.00
Candidate 1
- cancerLeukemiadictionary0.60
Registered trialsNCT03249870
Curated evidence
Evidence citing this paper (0)
Data not yet available